STOCK TITAN
  1. Home
  2. News
  3. RIGL

Rigel Pharmaceuticals - RIGL STOCK NEWS

Welcome to our dedicated news page for Rigel Pharmaceuticals (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rigel Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rigel Pharmaceuticals's position in the market.

News
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. grants stock options to employees, including Chief Medical Officer Lisa Rojkjaer, as an inducement for employment. The options vest over four years with a one-year cliff, and additional options are tied to future performance conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
News
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rhea-AI Summary
Rigel Pharmaceuticals announces promising results of olutasidenib in treating mIDH1 acute myeloid leukemia patients who failed venetoclax-based regimens. The study shows a 43.8% composite complete remission rate and favorable safety profile, offering hope for challenging cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
none
-
News
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. appoints Dr. Lisa Rojkjaer as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer brings over 20 years of industry experience in clinical development, regulatory affairs, and hematology/oncology. Her appointment aims to strengthen Rigel's clinical portfolio and support ongoing collaborations for potential new therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
management
News
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. reported a total revenue of $35.8 million in the fourth quarter of 2023, fueled by increased sales of TAVALISSE and REZLIDHIA. The company expanded its product portfolio with the acquisition of GAVRETO, focusing on commercial expansion and strategic collaborations. Financially, Rigel reported a net income of $0.7 million for Q4 2023 and a net loss of $25.1 million for the full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
earnings
-
News
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (RIGL) will report its Q4 and full year 2023 financial results on March 5, 2024. Senior management will host a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
conferences earnings
-
News
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. acquires U.S. rights to GAVRETO® (pralsetinib), an FDA-approved therapy for RET fusion-positive lung and thyroid cancer. GAVRETO generated $28M in U.S. sales in 2023, expanding Rigel's portfolio and leveraging existing infrastructure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.07%
Tags
acquisition
News
Rigel Pharmaceuticals Provides Business Update
Rhea-AI Summary
Rigel Pharmaceuticals, ticker symbol RIGL, reported preliminary fourth quarter 2023 total revenue of approximately $35.7 million, including record TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 million. The company also announced strategic alliances with MD Anderson and CONNECT to advance REZLIDHIA in AML, other cancers, and glioma, showing significant growth in its commercial hematology-oncology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
none
-
News
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (RIGL) grants 377,900 stock options to non-executive employees as an inducement for employment, in accordance with NASDAQ Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced a collaboration with CONNECT to conduct a Phase 2 clinical trial to evaluate REZLIDHIA® (olutasidenib) in combination with temozolomide as maintenance therapy in newly diagnosed pediatric and young adult patients with high-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutation. The collaboration will include olutasidenib in CONNECT's TarGeT-D, a molecularly guided Phase 2 umbrella clinical trial for HGG. Rigel will provide funding up to $3 million and study material over the four-year collaboration. The primary objective of the olutasidenib arm of the trial is to estimate progression-free survival. The study is estimated to begin enrolling patients in the first half of 2024 and will fulfill Rigel's post-marketing pediatric study requirement related to the FDA approval of REZLIDHIA in relapsed or refractory (R/R) AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
clinical trial
News
Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announces CEO's presentation at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
Stock RIGL logo
Rigel Pharmaceuticals

Nasdaq:RIGL

RIGL Rankings

#3790 Ranked by Market Cap
#1990 Ranked by Stock Gains
N/A Ranked by Dividends

RIGL Stock Data

210.49M
146.96M
2.11%
61.38%
2.86%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About RIGL

rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.